The absolute risk for thyroid cancer is low among patients receiving GLP-1 RA therapy, but risk is elevated in the first year of treatment.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

Redmond, founder and CEO of Dr. Stephanie’s Supplements, showcased her products, which she described as the latest innovations in supplement options for hormone and metabolic health, including a ...

The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Ozempic works by mimicking the hormone GLP-1, which suppresses hunger and regulates blood sugar levels. All semaglutide ...

New industry rules require visual size checks or GP medical records for online fat jab purchases. The updated guidelines ...

Rising consumer demand for fewer empty calories is pushing the snack and beverage giant to offer options with less sodium, fat and artificial ingredients.

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...